Indegene Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Indegene kazanç ve gelirin sırasıyla yıllık 20.4% ve 14.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 19.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.6% olacağı tahmin edilmektedir.
Anahtar bilgiler
20.4%
Kazanç büyüme oranı
19.59%
EPS büyüme oranı
| Life Sciences kazanç büyümesi | 24.1% |
| Gelir büyüme oranı | 14.5% |
| Gelecekteki özkaynak getirisi | 16.60% |
| Analist kapsamı | Good |
| Son güncelleme | 04 May 2026 |
Gelecekteki son büyüme güncellemeleri
Analiz Makalesi • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Analiz Makalesi • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Analiz Makalesi • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Recent updates
Anlatı Güncellemesi • Jun 02
INDGN: Tax Resolution Path And Dividend Prospects Will Drive Future Upside
Analysts have left their fair value estimate for Indegene broadly unchanged at around ₹592. A slightly higher discount rate and a marginally higher future P/E assumption are the main reasons cited for maintaining the same price target.Anlatı Güncellemesi • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Analiz Makalesi • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Anlatı Güncellemesi • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Anlatı Güncellemesi • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
Yeni Anlatı • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 24
INDGN: Steady Fair Value And Upcoming Board Review Will Support Upside Potential
Analysts have kept Indegene's fair value estimate steady at ₹603.0, with only marginal tweaks to assumptions such as the discount rate and future P/E. This reflects fine tuning of their valuation framework rather than a major shift in view.
Yeni Anlatı • Mar 14
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Anlatı Güncellemesi • Mar 05
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have trimmed their price target for Indegene slightly from about ₹606 to ₹603, reflecting modest tweaks to fair value, discount rate and future P/E assumptions while keeping revenue growth and profit margin expectations effectively unchanged. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for the quarter ended December 31, 2025 under IND AS, along with the auditors' limited review report (Key Developments).Anlatı Güncellemesi • Feb 19
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Analysts have kept their fair value estimate for Indegene steady at ₹605.86 per share, with only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding this price target reaffirmation. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for Indegene and its subsidiaries for the quarter ended December 31, 2025, prepared under IND AS, along with the auditors' limited review report (company filing).Anlatı Güncellemesi • Feb 04
INDGN: Upcoming Board And Shareholder Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene from ₹609.63 to ₹605.86, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A board meeting is scheduled for January 29, 2026, to review unaudited consolidated financial results for the quarter ended December 31, 2025, under INDAS, along with the auditors' limited review report (company filing).Analiz Makalesi • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Anlatı Güncellemesi • Jan 08
INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.Anlatı Güncellemesi • Dec 23
INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).Anlatı Güncellemesi • Dec 09
INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum
Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions. What's in the News Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing) Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement) Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement) Valuation Changes The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.Anlatı Güncellemesi • Nov 25
INDGN: Upcoming Board Meeting and Expansions Will Drive Continued Momentum
Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions. What's in the News A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).Anlatı Güncellemesi • Nov 10
INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance
Narrative Update on Indegene Price Target Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics. What's in the News Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025.Analiz Makalesi • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Analiz Makalesi • Jul 23
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
There wouldn't be many who think Indegene Limited's ( NSE:INDGN ) price-to-earnings (or "P/E") ratio of 32.5x is worth...Yeni Anlatı • May 11
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.Analiz Makalesi • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Analiz Makalesi • Feb 25
Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may consider...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2029 | 55,311 | 7,484 | 7,496 | 7,821 | 4 |
| 3/31/2028 | 48,306 | 6,380 | 6,836 | 7,679 | 7 |
| 3/31/2027 | 43,059 | 5,112 | 4,813 | 6,252 | 7 |
| 3/31/2026 | 35,105 | 4,011 | 6,065 | 6,508 | N/A |
| 12/31/2025 | 32,627 | 4,390 | N/A | N/A | N/A |
| 9/30/2025 | 30,410 | 4,458 | 4,683 | 5,094 | N/A |
| 6/30/2025 | 29,236 | 4,354 | N/A | N/A | N/A |
| 3/31/2025 | 28,393 | 4,067 | 4,119 | 4,419 | N/A |
| 12/31/2024 | 27,567 | 3,839 | N/A | N/A | N/A |
| 9/30/2024 | 27,097 | 3,730 | 4,302 | 4,377 | N/A |
| 6/30/2024 | 26,586 | 3,560 | N/A | N/A | N/A |
| 3/31/2024 | 25,896 | 3,367 | 4,970 | 5,077 | N/A |
| 12/31/2023 | 25,489 | 2,907 | 3,871 | 4,100 | N/A |
| 6/30/2023 | 23,927 | 2,487 | N/A | N/A | N/A |
| 3/31/2023 | 23,061 | 2,661 | 1,114 | 1,302 | N/A |
| 3/31/2022 | 16,646 | 1,648 | 2,723 | 2,970 | N/A |
| 3/31/2021 | 9,806 | 1,857 | 1,514 | 1,720 | N/A |
| 3/31/2020 | 6,436 | 558 | 162 | 223 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: INDGN 'nin tahmini kazanç büyümesi (yıllık 20.4% ) tasarruf oranının ( 6.9% ) üzerindedir.
Kazançlar ve Piyasa: INDGN şirketinin kazançlarının (yıllık 20.4% ) Indian pazarından (yıllık 16.1% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: INDGN şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: INDGN şirketinin gelirinin (yıllık 14.5% ) Indian pazarından (yıllık 10.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: INDGN şirketinin gelirinin (yıllık 14.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: INDGN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.6 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/11 15:53 |
| Gün Sonu Hisse Fiyatı | 2026/06/11 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Indegene Limited 14 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Deep Shah | 360 ONE Capital Market Private Limited |
| Rajiv Berlia | Citigroup Inc |